By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
2d
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research
Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...
The US Food and Drug Administration has issued emergency use authorization (EUA) for the Covid-19 vaccine developed by Pfizer and BioNTech. After months of development, emergency use was authorized ...
KALAMAZOO, Mich. -- Even though U.S. health officials authorized the emergency use of Pfizer's COVID-19 vaccine, getting the pandemic under control will take time and effort. One of the biggest steps ...
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...
Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results